Comparison of inhaled corticosteroids: An update

Annals of Pharmacotherapy

Volumn 43, Issue 3, 2009, Pages 519-527

  William Kelly, H ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Asthma; Inhaled corticosteroids; Pharmacodynamics, pharmacokinetics

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID DERIVATIVE; FATTY ACID; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; ITRACONAZOLE; KETOCONAZOLE; LONG ACTING DRUG; MOMETASONE FUROATE; RITONAVIR; TRIAMCINOLONE ACETONIDE;

AREA UNDER THE CURVE; ASTHMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CONTROL; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INFORMATION; DRUG POTENCY; ESTERIFICATION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; HUMANS; NEBULIZERS AND VAPORIZERS; PREGNENEDIONES; TREATMENT OUTCOME;

EID: 62949243372     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L546     Document Type: Review

References (70)

1. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Full report of the Expert Panel: guidelines for the diagnosis and management of asthma (EPR-3) 2007. www.nhlbi.nih.gov/guidelines/asthma (accessed 2008 Nov 25).
2. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs 2008;68:1741-70.
3. Derom E, Van De Velde V, Marissens S, Engelstatter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on Cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18:328-36.
4. Lee DKC, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate asthma. Chest 2005;127:851-60.
5. Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006;41:954-61.
6. O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001;86:397-404.
7. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001;61:1325-50.
8. NHLBI, National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 2, Publication No. 97-4051. Bethesda, MD: US Department of Health and Human Services, 1997.
9. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 1998;32:220-32. DOI 10.1345/aph.l7014
10. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004;1:356-63.
11. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91: 326-34.
12. Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:469-88.
13. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007;20:23-35.
14. Derendorf H, Nave R, Drollman A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28:1042-50.
15. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimit- telforschung 1998;48:956-60.
16. Jaffuel D, Demoly P, Gougat C, et al. Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 2000;162:57-63.
17. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2005;(2):CD002310.
18. Masoli M, Weatherall M, Holt S, Beasley R. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Child 2004;89:902-7.
19. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004;23:552-8.
20. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001 ; 164:1392-7.
21. Nathan RA, Nolop KB, Cuss FM, Lorber RR. A comparison of double- strength beclomethasone dipropionate (84 μg) MDI with beclomethasone dipropionate (42 μg) MDI in the treatment of asthma. Chest 1997; 112:34-9.
22. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-83.
23. Thorsson L, Edsbäcker S, Källén A, Löfdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001;52:529-38.
24. Dolovich MA, Maclntyre NR, Dhand R, Gross NJ, Hess DR, Pierson DJ. Consensus Conference on Aerosols and Delivery Devices. Respir Care 2000;45:588-776.
25. Liang J, Asmus MJ, Hochaus G, Chesrown S, Hendeles L. Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. Pharmacotherapy 2002;22:947-53.
26. Wilson AM, Dempsey OJ, Coutie WJR, Sims EJ, Lipworth BJ. Importance of drug device interaction in determining systemic effects of inhaled corticosteroids. Lancet 1999;353:2128.
27. Kanniess F, Richter K, Bohme S, Jorres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001;14:141-7.
28. Lipworth BJ, Sims EJ, Das SK, Buck H, Paterson M. Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol 2005;94: 675-81.
29. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001;119:1322-8.
30. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-8.
31. Phillips K, Oborne J, Harrison TW, Tattersfield AE. Use of sequential quadrupling dose regimens to study efficacy of inhaled corticosteroids in asthma. Thorax 2044;59:21-5.
32. Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids. Chest 1999;115:1278-84.
33. Kelly HW. Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469-78.
34. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;106:1209-26.
35. Mackie AE, McDowall JE, Ventresca P, Bye A, Falcoz C, Daley-Yates PT. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin Pharmacokinet 2000;39(suppl 1): 17-22.
36. Kunka R, Andrews S, Pimazzoni M, et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 2000;94(suppl B):S10-6.
37. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:1215-22.
38. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoralkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122:510-6.
39. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005;18:379-85.
40. Szefler SJ, Warner J, Staab D, et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate in children: a 6-month, open-label, randomized trial. J Allergy Clin Immunol 2002; 110:45-50.
41. Fairfax AJ. The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma. Respir Med 2000;94(suppl):S31-6.
42. -1) in patients with asthma. Respir Med 2001 ; 95:212-20.
43. Horiguchi T, Hayashi N, Ohira D, M, et al. Usefulness of HFA-beclomefhasone dipropionate for adult patients with bronchial asthma: randomized crossover study with fluticasone. J Asthma 2006;43:509-12.
44. Ohbayashi H, Adachi M. Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double- cross study. Allergol Int 2008;57:231-9.
45. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroal- kane-134A beclomefhasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma 2005;42:257-63.
46. Robroeks CMHHT, van de Kant KDG, van Vliet D, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol 2O08;100: 601-7.
47. Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14- day dose-response study. J Pharm Pharmacol 1999;51:263-9.
48. Richards J, Hirst P, Pitcairn G, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001;14:197-208.
49. Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hy- drofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol 2001;87:405-11.
50. Newman S, Salmon A, Ruediger N, Drollman A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375-84.
51. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary- adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005;128:1104-14.
52. van den Brink KI, Boorsma M, Staal-van den Brekel AJ, et al. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol 2008;66:27-35.
53. Fardon TC, Lee DKC, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-6.
54. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001;51:400-9.
55. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
56. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005;90:4394-8.
57. Molimard M, Girodet P-O, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf 2008;31:769-74.
58. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004;38:46-9. DOI 10.1345/aph.lD222
59. De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2003;2: 72-5.
60. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006;148: 377-83.
61. Boulet LP. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 2004; 10:15-21.
62. Masoli M, Weatherall M, Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology 2005;10:183-8.
63. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004;9:528-34.
64. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K,Harrison JE. Mometasone furoate administered once daily is as effective as twice daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000; 106:485-92.
65. Berger WE, Ford LB, Mahr T, et al. Efficacy and safety of fluticasone propionate 250 μg administered once daily in patients with persistent asthma treated with or without inhaled corticosteroids. Ann Allergy Asthma Immunol 2002;89:393-9.
66. Subbarao P, Duong M, Adelrofh E, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2006;117:1008-13.
67. Petersen R, Agertoft L, Pedersen S. Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma. Eur Respir J 2004;24:932-7.
68. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) international study group. N Engl J Med 1997;337:1405-11.
69. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004;170:836-44.
70. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.